Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 19/20 | 0.51 |
| ▸ | DLK1 | P80370 | 1/20 | 0.48 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21262505 | 1.00 | MAP3K12 (0.51) | MAP3K12DLK1MAP3K13 | |
| SCHEMBL24196362 | 0.84 | MAP3K12 (0.51) | MAP3K12DLK1MAP3K13 | |
| SCHEMBL31322038 | 0.77 | SOS1 (0.45) | MAP3K12DLK1MAP3K13 | |
| SCHEMBL17076749 | 0.76 | MAP3K12 (0.54) | MAP3K12DLK1MAP3K13 | |
| SCHEMBL30605628 | 0.76 | MAP3K12 (0.45) | MAP3K12DLK1MAP3K13 | |
| SCHEMBL21672315 | 0.76 | MAP3K12 (0.54) | MAP3K12DLK1MAP3K13 | |
| SCHEMBL21262509 | 0.75 | MAP3K12 (0.47) | MAP3K12DLK1 | |
| SCHEMBL30137173 | 0.75 | MAP3K12 (0.47) | MAP3K12DLK1 | |
| SCHEMBL21246740 | 0.74 | CHRNA7 (0.50) | — | |
| SCHEMBL21262096 | 0.73 | NR3C2 (0.35) | MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | BCL6, BCL6B, BCL3 | MAP3K12 1874/4885DLK1 885/4885MAP3K13 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.